

13 May 2026

ASX Announcement

Nasodine patent accepted in Canada

- This is the second Nasodine patent that has been granted in Canada, the first relating to use in the Common Cold
- New patent covers the use of Nasodine Nasal Spray and other Nasodine products in relation to treating and reducing viral shedding associated with SARS-CoV-2 (COVID)

Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) is pleased to announce that its patent titled "Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes" has been accepted in Canada.

The patent protects the use of Nasodine Nasal Spray ("Nasodine") or any other intranasal povidone-iodine (PVP-I) preparations as a method of reducing the viral load of SARS-CoV-2 in the nose. Granted claims also cover pre-exposure prophylaxis (preventative use prior to exposure) against SARS-CoV-2.

This patent, which expires in 2040, has also been accepted and/or granted in the United States, Europe, Australia, and multiple other countries.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). Its first product, Nasodine® Nasal Spray (0.5% PVP-I), has been introduced into the United States, Singapore, and Fiji & South Pacific. Nasodine Nasal Spray was also recently approved for marketing in Indonesia and the Company is pursuing approval in the Philippines and other markets. Nasodine® Throat Spray is the first follow-on product, and is now available in Singapore and Fiji. Firebrick recently announced plans for a total of up to four products in the Nasodine range and expansion of sales to up to 10 markets over three years. For further information, visit firebrickpharma.com

Contacts:

Media contact:

Matthew Wright, NWR Communications
matt@nwrcommunications.com.au

Shareholder Company contact:

Kam Watson, Firebrick Pharma
investors@firebrickpharma.com